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Introduction
Myeloid-derived suppressor cells (MDSCs) negatively regulate cell-mediated immunity by inhibiting T cell 
proliferation and inducing Treg responses (1). Although widely characterized by their expression of  Gr-1 and 
CD11b markers, MDSCs can be further subdivided into monocytic CD11b+Ly6G–Ly6Chi MDSCs and gran-
ulocytic CD11b+Ly6G+Ly6Clo MDSC subsets in mice (1). Among many different suppressor mechanisms 
of  MDSCs (2), the production of  NO by the activity of  the inducible NO synthase (iNOS) appears to be a 
suppressive tool mainly described for the monocytic MDSC (M-MDSC) subset (3). However, to date, NO 
production and its direct role in T cell suppression have been shown only in cocultures of  T cells stimulated 
for proliferation with MDSCs in vitro and ex vivo (4–7). The demonstration of  direct NO-dependent T cell 
suppression by MDSCs in vivo is lacking.
Suppressive effects of  MDSCs have been mainly observed in tumor biology, but there is increasing evi-
dence of  similar effects in infectious disease conditions, especially for the M-MDSC subset in tuberculosis 
(TB) (8). Previously, we observed that MDSCs are highly induced in patients suffering from TB and in chil-
dren coinfected with HIV (9, 10). MDSC accumulation was also proved to be a critical regulator in murine 
Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high 
numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. 
tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We 
found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete 
Freund’s adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis 
strongly expanded CD11b+ myeloid cells in the spleen, leading to T cell suppression of proliferation 
and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b+Ly6ChiCD115+ 
iNOS/Nos2+ monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation 
signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and 
then positioned in the white pulp areas. Notably, within 6–24 hours, in a Nos2-dependent fashion, 
they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T 
cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly 
suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate 
that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill 
DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated 
also in clinical trials.
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models of  live Mycobacterium tuberculosis infection (11). Whether vaccines containing killed M. tuberculosis 
would also induce MDSCs remains unclear.
Among the carrier substances for antitumor or antipathogen vaccines, incomplete Freund’s adjuvant (IFA), 
used under the name Montanide ISA-51 VG, is a suitable and widely distributed mineral oil–based adjuvant for 
human clinical studies with good antigen responses but also some adverse effects (12, 13). Another preparation, 
CFA, was developed in 1942 and since then has been widely used as a vaccine adjuvant in experimental ani-
mals (14). Since CFA is composed of IFA containing heat-killed and dried M. tuberculosis, it can be considered 
as an M. tuberculosis vaccine. Notably, unclear tolerogenic effects had been observed after CFA vaccination in 
animals (14). On the one hand, CFA is a critical component for the induction of autoimmunity in models of  
experimental autoimmune encephalomyelitis (15, 16); on the other hand, injection of CFA could also prevent 
autoimmunity, such as the onset of type I diabetes in NOD mice (17) and ameliorated Parkinson’s disease in 
rats (18). While the pathogen-induced adjuvant effects can be explained by mycobacterial triggering of TLR2 
and TLR4, the tolerogenic mechanisms of CFA are not understood. The possible suppressive effects, besides 
their immunostimulatory function by IFA and other adjuvants in tumor vaccination studies, have been reviewed 
before (13). CFA-based tumor vaccines could induce suppressive CD11b+ immune cells (7, 19), while in an 
alum-based vaccine, B cell immune responses were boostered by CD11b+ cells (19). However, these questions 
remain unclear: whether M. tuberculosis or IFA/Montanide will be able to induce MDSCs, which MDSC subsets 
will become activated, and what are the major target cells of their suppression in vivo.
Previously, we described a simple and reliable protocol to generate murine MDSCs in vitro from 
murine BM precursor cells with GM-CSF (20). The generation of  such human or murine M-MDSCs 
in vitro can be performed by following a 2-step protocol that, first, converts classical monocytes (Ly6Chi 
or CD14+) into monocytes “licensed” for suppression (L-Mono) that also can be considered as resting 
M-MDSCs and, second, converts L-Mono into activated M-MDSCs that release the suppressor molecules 
NO in the murine and IDO in the human system (21). This in vitro differentiation model exemplifies the 2 
steps of  signaling for M-MDSC induction that are relevant also in vivo (1). While the combination of  LPS 
and IFN-γ for the second step of  MDSC activation constituted one of  the strongest signals (22), cocktails 
of  proinflammatory cytokines were also effective (21). While the infiltration of  MDSCs at vaccination 
sites and lymph nodes has been observed before using Mycobacterium bovis BCG, only local T cell respons-
es seemed to be affected in these organs (23).
The targets of  MDSC-mediated suppression were mainly identified as macrophages, NK cells, 
and CD4+ or CD8+ T cells that were tested for their phagocytic activity, proliferative capacity, or 
their production of  cytokines (2, 24). DCs, which represent key mediators to induce adaptive immune 
responses, can be affected by MDSCs in tumors, mostly by converting them into tolerogenic phe-
notypes (25). Other regulatory myeloid cells, such as regulatory macrophages, have been shown to 
impair DC maturation indirectly by inducing Tregs (26). However, whether MDSCs effect DC func-
tion during infection or vaccination has not been addressed yet. Here, we show that MDSCs induce 
apoptosis of  BM-generated DCs (BM-DCs) in vitro and conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs) in the T cell areas of  the splenic white pulp of  mice. DC killing depended on iNOS and 
the release of  NO. Our data demonstrate that a M. tuberculosis vaccine, such as a component of  CFA, 
induces licensing and activation of  MDSCs in mice. These CFA-induced MDSCs readily produced 
NO and were primarily found to induce apoptosis in DC subsets rather than T cells.
These results suggest a potentially new immune evasion mechanism of  DC killing by M. tuberculosis 
that does not rely on live bacteria but occurs after killed M. tuberculosis vaccination. Given the pivotal role of  
DCs for vaccine success, and new TB control strategies by applying revaccination, these potentially novel 
findings may significantly effect the future design and monitoring of  M. tuberculosis vaccination strategies.
Results
CFA expands the myeloid cell compartment in the splenic red pulp. To examine how M. tuberculosis vaccines influ-
ence the composition of  the myeloid compartment and MDSC generation and activation, most of  the 
following experiments were performed according to defined protocols of  immunization. These include 
application of  CFA alone or followed by a second IFA or CFA injection. Optionally, short-term challenges 
by LPS/IFN-γ injections were performed before spleens were analyzed (Figure 1A). When we injected 
mice s.c. with a single CFA dose splenic cell numbers increased, similar to that in previous reports (7, 27), 
and a double immunization by the CFA/CFA regimen further increased the number of  splenic myeloid 
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cells (Figure 1B). The frequency of  granulocytic Ly6C+Ly6G+ cells was boosted especially after the first 
and second CFA application, and the frequencies of  Ly6Chi monocytic cells were moderately increased 
(Figure 1C). To address the spatial localization of  the endogenous, CFA-expanded cells within the spleen, 
we stained sections from cryopreserved spleens from healthy, CFA-, and CFA/CFA-injected mice for dif-
ferent markers. All Gr-1+ cells were restricted to the splenic red pulp area independent of  their expansion 
by CFA or CFA/CFA immunizations (Figure 1D). To gain a more detailed insight on the phenotype of  
CFA-expanded cells, we employed markers frequently used for the identification of  MDSCs for immuno-
fluorescence staining of  spleens from CFA-treated mice. CD11b+ cells coexpressed Gr-1, Ly6C, and Ly6G 
markers but very little F4/80 (Supplemental Figure 1; supplemental material available online with this 
article; https://doi.org/10.1172/jci.insight.128664DS1), a finding compatible with the hypothesis that the 
CFA-expanded cells represent neutrophilic and monocytic cells rather than resident red pulp macrophages 
of  embryonic origin (28). All together, these data suggest that CFA or CFA/CFA administration triggered 
the expansion and accumulation of  myeloid spleen cells that phenotypically resemble both monocytic 
Ly6ChiLy6G– and granulocytic Ly6CloLy6G+ MDSC subsets.
Splenic CD11b+ cells of  CFA/CFA-immunized mice acquire NO-dependent T cells suppressor capacity. Next, we asked 
whether the expansion of splenic myeloid cells after the different CFA immunizations induced suppressor func-
tions. For this purpose, we immunized mice either once with CFA or twice with the combinations CFA/IFA or 
CFA/CFA. Three days later, CD11b+ cells from the spleens of these mice were purified as a source of myeloid 
cells containing the potential MDSC subsets. Their ability to produce NO was tested by an overnight treatment 
with LPS/IFN-γ, a method that had been established before ex vivo for splenic MDSCs (22) and as shown here 
in vitro (Supplemental Figure 2). Only splenic CD11b+ cells derived from mice immunized with the CFA/CFA 
protocol produced amounts of NO that reached the levels of in vitro BM-generated MDSCs (Figure 2A).
To test whether this correlated with the acquisition of  T cell suppressor potential, splenic CD11b+ cells 
from the same groups of  immunized mice were cultured with CD3/CD28 antibody-stimulated naive T 
cells. Detection of  T cell proliferation by CFSE dilution indicated that only CD11b+ cells from CFA/CFA 
mice acquired T cell suppressor potential on CD4+ and CD8+ T cells to the same levels as observed with 
BM-MDSCs (Figure 2, B and C). T cell suppression by CD11b+ cells from CFA/CFA mice depended on 
NO release, because addition of  the iNOS-inhibitor L-NMMA restored T cell proliferation (Figure 2, B 
and C). Thus, ex vivo–isolated splenic CD11b+ cells from CFA/CFA-immunized mice but not mice immu-
nized with CFA or the CFA/IFA combination underwent a monocyte-licensing process, which allowed the 
acquisition of  MDSC suppressor potential on stimulated T cells from unperturbed mice.
To further test whether the T cells within the spleens that contain CD11b+ suppressor cells appear as 
suppressed T cells, we labeled spleen cells obtained from control mice or CFA-, CFA/IFA-, and CFA/
CFA-immunized mice with CFSE and stimulated them with CD3/CD28 antibodies for 4 days. CFA/CFA 
immunization significantly impaired the proliferation capacity of  endogenous CD4+ and CD8+ T cells (Fig-
ure 2D). When the same experiment was performed, but splenic CD11b+ cells were removed by magnetic 
beads before culture, the T cell proliferation of  CFA/CFA-immunized mice was not affected (Figure 2E). 
These data clearly indicate that in spleens of  CFA/CFA mice suppressive CD11b+iNOS+ cells are generat-
ed that control the proliferation capacity of  naive or endogenous T cells by NO production ex vivo.
Since NO production for suppressor function of  CD11b+ cells is most likely derived from monocytic 
cells (Supplemental Figure 1, A and B), and splenic monocytes reside in the red pulp and subcapsular sinus 
(29) but are not localized within the T cell areas of  the white pulp, the question remained of  which anatom-
ical location suppressor cells produce NO and suppress T cells in vivo.
LPS/IFN-γ challenge accumulates CD11b+CD115+iNOS+ M-MDSCs in splenic T cell areas adjacent to DCs. 
Since ex vivo–isolated splenic CD11b+ cells acquired iNOS-dependent T cell suppressor function, we 
attempted to detect iNOS in spleens of  mice immunized with CFA or CFA/CFA. Immunofluorescence 
staining of  cryopreserved spleens 3 days after the last CFA injection did not reveal any iNOS+ cells in all 
groups of  immunized mice (Figure 3A). Since the optimal time point for iNOS detection in the spleen 
after s.c. CFA immunization may be difficult to determine, we injected CFA/CFA-immunized mice peri-
toneally with the established LPS/IFN-γ regimen to induce iNOS. After 6 hours, this treatment induced 
massive infiltrations of  CD11b+ cell but moderate Ly6G+ cell accumulation in the CD3+ T cell areas of  
the white pulp in both WT and Nos2–/– mice (Figure 3B). The infiltrates also appeared as iNOS+ cells in 
sections of  WT mice but not of  Nos2–/– mice (Figure 4A), confirming the specificity of  our iNOS detec-
tion. Next, we asked whether the iNOS detection would indeed lead to the release of  NO and whether 
4insight.jci.org   https://doi.org/10.1172/jci.insight.128664
R E S E A R C H  A R T I C L E
the LPS/IFN-γ challenge alone was responsible for NO induction but required preimmunization of  the 
mice with CFA/CFA. Therefore, we challenged untreated control mice and mice treated with CFA only 
or CFA/CFA systemically with LPS/IFN-γ. After 6 hours, the NO production by DAQ staining of  
splenic cryosections was highly increased in the T cell areas of  CFA/CFA-immunized mice, while it was 
only moderately detectable in spleens of  mice injected with LPS/IFN-γ only or CFA plus LPS/IFN-γ–
treated mice (Figure 4B). Together, despite the fact that spleens of  CFA/CFA-injected mice contain 
functionally suppressive MDSCs with NO-producing capacity (Figure 2), iNOS was not detectable in the 
spleens of  these mice but required LPS/IFN-γ challenge to be visualized.
Figure 1. CFA administration induces myeloid cell expansion and accumulation in the splenic red pulp. (A) General 
scheme of single and repetitive immunizations. Mice received a single s.c. dose of CFA at day 0 alone or second dose of 
IFA or CFA at day 12. Then spleens were analyzed at day 15. Optionally, mice were challenged with LPS/IFN-γ at day 15 
for 6 hours or 24 hours before spleens were further analyzed. (B) C57BL/6 mice were injected s.c. with CFA or CFA/CFA or 
remained untreated before spleens were analyzed according the scheme in A. Spleen cellularity was counted at day 15 (9 
independent experiments with replicates: Ctrl = 14, CFA = 19, CFA/CFA = 21). (C) Mice were injected as described above, 
and spleen cells were analyzed by FACS for Ly6C+ and Ly6G+ cell subsets. Numbers above the dot plots represent the 
percentages of the red gated Ly6Chi gated cells or the top right quadrant for Ly6G+ cells (4 independent experiments with 
replicates: Ctrl = 9, CFA = 14, CFA/CFA = 11). (D) Spleens from the indicated mice were collected at day 15 and cryosections 
were stained for Gr-1 for myeloid cells and B220 to indicate B cell zones as borders of the white pulp. Scale bars: 500 μm. 
Microscopy data are representative of at least 3 independent experiments with (n = 3 mice) for each group. (B and C) Sta-
tistical significance was assessed by comparison of control versus treated mice. Statistics by 1-way ANOVA with multiple 
comparisons and Tukey’s post test. **P < 0.01, ***P <0.005, ****P < 0.0001. Values correspond to the mean ± SD.
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Figure 2. Only CD11b+ cells isolated from CFA/CFA mice produce substantial amounts of NO and suppress T cell proliferation. (A) CD11b+ cells from 
spleen cells of untreated (Ctrl) and CFA-, CFA/IFA-, and CFA/CFA-treated mice were isolated by MACS and compared with in vitro–generated BM-MDSCs 
for their NO production by Griess assay after overnight stimulation with LPS/IFN-γ. Values correspond to NO production by 2 × 106 cells (3 independent 
experiments with n = 8 replicates, except BM-MDSCs with n = 6). (B) T cell suppression assays. CFSE-labeled bulk T cells isolated from naive mice were 
stimulated with CD3/CD28 antibodies and cultured for 4 days with MACS-purified CD11b+ cells from untreated and CFA-, CFA/IFA-, and CFA/CFA-treated 
mice or in vitro BM-generated MDSCs in the presence or absence of L-NMMA. Example assay showing the gating for proliferated CFSElo cells. (C) Pooled 
data of individual experiments, as shown in B, are displayed. For T cells only, BM-MDSC, CFA/CFA plus L-NMMA (n = 3). For CTRL, CFA, CFA/IFA, CFA/CFA 
(n = 4). For BM-MDSC plus L-NMMA (n = 2). (D) Ex vivo bulk T cell proliferation assay. Spleens from untreated (Ctrl, n = 14 mice), CFA- (n = 16), CFA/IFA- (n 
= 15), and CFA/CFA-treated mice (n = 16) were CFSE labeled and then stimulated with CD3/CD28 antibodies for 4 days. The percentages of proliferated 
CFSElo cells within the CD4+ and CD8+ T subsets are shown. (E) Ex vivo bulk T cell proliferation assay. CD11b+ cell–depleted spleens from untreated and CFA-
, CFA/IFA-, and CFA/CFA-treated mice (n = 3) were CFSE labeled and then stimulated with CD3/CD28 antibodies for 4 days. The percentages of proliferated 
CFSElo cells within the CD4+ and CD8+ T subsets are shown. Statistical significance was assessed by comparison of sorted cells from control versus treated 
mice (A) or T cells only versus T cells cocultured with ex vivo–sorted CD11b+ cells from treated mice (C) or bulk splenic T cells from control versus treated 
mice (D and E). Statistics by 1-way ANOVA with multiple comparisons and Tukey’s post test. **P < 0.01,****P < 0.0001.
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Surprisingly, higher resolution microscopy revealed that iNOS+ cells were closely associated with 
CD11c+ DCs in the T cell areas and partially seemed to form synapses (Figure 4C). Counterstaining with 
CD115 identified the iNOS+ cells in spleen sections of  CFA/CFA plus LPS/IFN-γ–injected mice as mono-
cytic cells, which appeared either as iNOSbright cells in the marginal zone and bridging channels (Figure 4D, 
BC and MZ) or as iNOSdull cells in the T cell areas (Figure 4E, T).
Together, these findings indicate that LPS/IFN-γ challenge induces a rapid accumulation of  granulo-
cytic and monocytic cells into the T cell areas after 6 hours. iNOS+CD115+ M-MDSCs releasing NO espe-
cially localize close to CD11c+ DCs. Substantial M-MDSCs infiltration and iNOS detection was restricted 
to mice that were preimmunized with the CFA/CFA protocol, while a single CFA or CFA/IFA immuni-
zations or LPS/IFN-γ challenge did not show this effect. It remained to be determined whether the appear-
ance of  iNOS+ M-MDSCs in the T cell areas had functional consequences.
NO-dependent DC killing by M-MDSCs in the splenic T cell areas of  CFA/CFA-immunized mice. We tested 
whether the observed iNOS+ M-MDSC infiltration of  the splenic T cell areas led to changes in the absolute 
numbers of  T cells or DCs as an indicator of  killing. We counted the cell numbers of  DCs and T cells in 
spleens of  CFA/CFA-immunized mice that were challenged for the established iNOS-inducing LPS/IFN-γ 
treatment or M. tuberculosis/IFN-γ. The CD11chiMHC-IIhi B220– cDCs numbers continuously decreased 
over 48 hours. In contrast, the numbers of  CD11c+B220– pDCs and both CD4+ and CD8+ T cell subsets 
increased over 48 hours under both challenge conditions (Figure 5A). Since apoptosis needs to be measured 
before the disappearance of  cells, we restricted further experiments to the earlier time points.
Splenic DC and T cell populations were analyzed by FACS for the appearance of  apoptotic cells, as 
detected by annexin V binding. After 24 hours, but not 6 hours, the frequency of  apoptotic annexin V+ 
Figure 3. Systemic LPS/IFN-γ administration induces MDSC infiltration into the splenic white pulp. (A) Spleens from untreated (Ctrl) and CFA- and CFA/
CFA-immunized mice were collected after 15 days, and cryosections were stained for iNOS, B220, and CD11c. (B) WT and Nos2–/– mice were CFA/CFA inject-
ed and challenged with i.p. LPS/IFN-γ administration for 6 hours. Then spleens were stained for B220, CD11b, Ly6G, and CD3 as indicated. All microscopy 
data are representative of 3 independent experiments (n = 3 mice). Scale bars: 100 μm.
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cDCs and annexin V+ pDCs substantially increased (Figure 5B). Systemic LPS-IFN-γ challenge without 
prior CFA/CFA immunization did not reveal any increase in apoptosis of  cDCs, while it partially induced 
apoptosis in pDCs (Figure 5B, violet). Interestingly, none of  these conditions increased CD4+ and CD8+ 
T cell apoptosis at both time points, while an antiapoptotic effect appeared in CD8+ T cells at 6 hours and 
only in Nos2–/– mice (Figure 5B). The antiapoptotic effect may result from the observed DC maturation 
after LPS/IFN-γ injection (Supplemental Figure 4A), which resulted in increased T cell activation (Supple-
mental Figure 4B), lending at least a transient antiapoptotic effect to the T cells.
To substantiate these findings, we determined the frequencies of  the same cell populations in the 
spleen. The cDCs frequencies were diminished at both 6 hours and 24 hours in WT mice but not in 
Nos2–/– mice. At the same time, the frequencies of  pDCs relatively increased, despite increased frequen-
cies of  apoptotic cells (Figure 5C). This, together with the higher absolute cell number of  pDCs, may 
suggest a simultaneous killing by MDSCs but also enhanced recruitment of  pDCs into the spleen, such 
as observed after viral infections (30).
Importantly, both reduced frequencies and increased apoptosis occurred for Nos2-dependent cDCs after 
LPS/IFN-γ injection, and a similar trend was observed with M. tuberculosis/IFN-γ, but only transiently after 
24 hours. Circulating cells, such as pDCs and CD4+ and CD8+ T cells, remained stable in their frequencies 
or were moderately increased. While pDCs showed increased apoptosis, T cells seemed not to be affected 
(Figure 5C). Thus, LPS/IFN-γ injection induced preferential cDC and pDC killing but spared T cells.
Figure 4. Systemic LPS/IFN-γ administration induces iNOS and NO production by CD115+ M-MDSCs interacting with CD11c+ DCs. (A) WT and Nos2–/– mice 
were injected as in Figure 3B but stained for B220, iNOS, CD11c, and CD3 markers as indicated or (B) with B220 and the NO-detecting reagent DAQ. T, T cell 
areas; B, B cell areas. (C) WT and Nos2–/– mice were injected with CFA/CFA plus 6-hour LPS/IFN-γ. The spleen sections were stained with B220, CD11c, and 
iNOS. Enlarged areas show marginal zone DCs (MZ-DCs) or DCs in the T cell area (T area-DCs) in close contact or forming synapse-like structures with iNOS+ 
cells. (D and E) Mice treated, as in B, stained with iNOS, B220 and CD115. BC, bridging channel; MZ, marginal zone. All microscopy data are representative 
of 3 independent experiments (n = 3 mice). Scale bars: 100 μm.
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Figure 5. MDSC-mediated DC killing is iNOS dependent. (A) C57BL/6 WT mice (n = 3) were immunized s.c. with CFA/CFA or were left untreated 
(without CFA) and challenged with LPS/IFN-γ, M. tuberculosis/IFN-γ, or vehicle (0h). Spleens were harvested after 6 hours, 24 hours, and 48 hours 
after the mice received the challenge injections, and the absolute cDC, pDC, and CD4+ and CD8+ T cell numbers were calculated from the frequen-
cies of the indicated surface marker stainings among the whole spleen cell counts. (B) C57BL/6 WT (n = 3) and Nos2–/– mice (n = 3) were used for 
immunization as above but only challenged with LPS/IFN-γ. The individual cell populations were stained using the indicated markers and analyzed 
by flow cytometry after 6 hours and 24 hours for the frequency of apoptotic cells using annexin V or (C) their live-cell frequencies were calculated. 
(D) DC in vitro killing assay. In vitro–generated BM-DCs were matured overnight with LPS and then cocultured at 1:1 ratio with M. tuberculosis–acti-
vated BM-MDSCs that were generated from WT or Nos2–/– mice and sorted into CD11b+Ly6ChiLy 6G– monocytic or CD11b+Ly6CloLy6G+ granulocytic cell 
subsets (n = 4 independent experiments). Apoptosis of DCs was determined by annexin V FACS staining and normalized to DC cultures without 
BM-MDSCs. (E) Cryosections of spleens from CFA/CFA plus LPS/IFN-γ–immunized mice were analyzed by confocal microscopy to assess apopto-
sis of CD11c+ DCs via TUNEL or FVF staining. B cell areas were identified by B220 staining. Scale bars: 60 μm. (F) Quantification of E at 24 hours. 
CD11c+TUNEL+ cells within the T cell zone of WT (n = 16) and Nos2–/– (n = 20) spleen cryosections were analyzed with StrataQuest software. (G) 
Cytospin preparations of LPS-matured BM-DC and M. tuberculosis–activated BM-MDSC cocultures to demonstrate CD11c+TUNEL+ DC killing in vitro. 
Statistics shown in black were performed using an unpaired 2-tailed t test. *P < 0.05, **P < 0.01, ***P < 0.001. Mean and SD are shown. Statistical 
P values shown in red were performed using 2-way ANOVA testing for changes over time, while no differences were found between the differential-
ly treated groups. Statistical P values shown in blue were performed using 2-way ANOVA testing for changes over time and between the WT and 
Nos2–/– mice. ANOVA analyses were performed without the group that received only LPS/IFN-γ (violet bars).
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BM-MDSC–mediated BM-DC killing in vitro. NO-mediated suppression and induction of  apoptosis of  T 
cells are among findings frequently reported as mechanisms of  M-MDSC function (31), findings which are 
also supported by our ex vivo data. Conversely, DC killing had not been reported in vitro. Therefore, we set 
up a series of  in vitro assays to study the effect of  M. tuberculosis on in vitro–generated M-MDSCs and on 
their effects on DCs and T cells.
MDSCs generated from murine BM with GM-CSF (BM-MDSCs) by our established protocol (20) 
recapitulated iNOS induction and NO production upon M. tuberculosis stimulation, which can be attributed 
mostly to M-MDSCs and to a much lesser extent to G-MDSCs, and increased suppression of  T cell pro-
liferation, all effects that were similar to those after LPS/IFN-γ stimulation (Supplemental Figure 2) and 
as observed previously (22). BM-MDSCs prevented CD25 upregulation, modified CD69 expression, and 
finally induced T cell apoptosis in vitro in an Nos2-dependent manner (Supplemental Figure 3). Thus, T cell 
suppression and apoptosis can be readily demonstrated in vitro and ex vivo but not in our in vivo settings.
To address DC killing in vitro, M. tuberculosis–activated BM-MDSCs were sorted into granulocytic or 
monocytic subsets of  WT mice and Nos2–/– mice and cocultured with LPS-matured BM-DCs. Only the 
monocytic BM-MDSC subset induced Nos2-dependent apoptosis of  DCs (Figure 5D). Similarly, LPS/IFN-γ–
activated BM-MDSCs but not unstimulated MDSCs induced apoptosis of  LPS- or CpG oligonucleotide–
matured BM-DCs in an iNOS-dependent manner, since the NO-inhibitor L-NMMA reverted apoptosis, as 
shown for annexin V by FACS (Supplemental Figure 5A) or TUNEL staining by confocal microscopy (Sup-
plemental Figure 5B). These data indicate that the M. tuberculosis– or LPS/IFN-γ–activated M-MDSCs subset 
within BM-MDSCs can directly kill BM-DCs by release of  NO in vitro, supporting our in vivo findings.
DC killing in the T cell areas detected in situ. To corroborate the DC killing data obtained so far, we further 
performed immunofluorescence staining of  the spleens. TUNEL staining detecting apoptosis at a relatively 
late stage did not reveal any dead cells at 6 hours in the spleen (Figure 5E). Using an earlier apoptosis mark-
er, FAM-VAD-FMK (FVF), we found individual CD11c+ cells that appeared with a positive nuclear stain-
ing, but these cells were too few for further statistical evaluation (Figure 5E, 6h inset). In contrast, after 24 
hours TUNEL+ cells were readily detectable in the T cell areas of  spleens in CFA/CFA plus LPS/IFN-γ–
injected mice (Figure 5E). To quantify DC apoptosis in the T cell areas, we used StrataQuest software with 
the same markers and costained T cells obtained from splenic sections of  WT and Nos2–/– mice by TUNEL 
(32). Indeed, a substantial proportion of  spleen sections showed increased frequencies of  CD11c+TUNEL+ 
cells in the T cell areas at 24 hours. This was not observed in sections from Nos2–/– mice, suggesting the 
induction of  NO-dependent DC apoptosis in T cell areas of  the spleen (Figure 5F). Since TUNEL+ spot 
staining did not seem to clearly colocalize with CD11c+ cell nuclei (Figure 5E, 24h, enlarged areas), as we 
had detected by FVF staining at 6 hours (Figure 5E, inset), we sought to confirm this apoptosis pattern by 
TUNEL staining with BM-DCs cocultured with activated BM-MDSCs for 24 hours in vitro. The in vitro–
cultured apoptotic BM-DCs showed a similar pattern of  TUNEL+ spots, which also did not fully colocalize 
with the nuclear DAPI staining (Figure 5G). Therefore, this 24-hour TUNEL staining pattern is compatible 
with the detection of  apoptotic bodies under in vivo conditions.
Together, our results indicate that pathogen-activated MDSCs rapidly infiltrate into the splenic T 
cell areas in CFA/CFA-immunized mice within 6 hours. After 24 hours iNOS-dependent induction of  
apoptosis of  cDCs and pDCs can be observed. Surprisingly, CD4+ and CD8+ T cell apoptosis was not 
detectable in any of  our in vivo conditions.
Discussion
Here, we addressed the question of  whether an IFA-based vaccine equivalent to human adjuvant Mon-
tanide ISA-51 VG that containing additional heat-killed M. tuberculosis (together called CFA) can induce 
functional MDSCs in mice. We found accumulating monocytic and granulocytic cells in the splenic red 
pulp after single CFA as reported previously (7, 19) but even more after CFA/CFA double immuniza-
tions. Functionally, only CD11b+ cells from spleens of  CFA/CFA but not otherwise immunized mice 
acquired NO-producing capacity and iNOS-dependent T cell suppressor activity after stimulation ex 
vivo, indicative of  MDSC induction. While iNOS expression or NO production was not detectable in 
situ in CFA/CFA-immunized mice, both could be activated by 6 hours after LPS/IFN-γ injection. This 
indicates that monocyte licensing for suppression had occurred in the spleen by the CFA/CFA treat-
ment, but no activation from L-Mono into M-MDSCs had occurred yet. These results are compatible to 
what we found before in vitro (21, 22). Both granulocytic and monocytic cells infiltrated the white pulp 
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T cell areas, but only CD11b+ CD115+ monocytic cells were counterstained as iNOS+. This phenotype 
is compatible with M-MDSCs (1). As a result of  the LPS/IFN-γ or M. tuberculosis/IFN-γ injections, we 
could observe NO-dependent apoptosis of  cDCs and pDCs while T cells seemed unaffected.
While CFA is a potent adjuvant, our data indicate that it can also induce immunosuppressive M-MD-
SCs when administered twice. While previous reports indicated suppressive effects of  CD11b+ cells already 
after a single application of  100 μL CFA on ConA-stimulated T cells (7, 19), we could not observe this 
using half  the dose to avoid open skin wounds at the injection site and by stimulating T cells with anti-
CD3/CD28 antibodies. Importantly, the M. tuberculosis content within the second CFA vaccine determined 
the immunological outcome, as demonstrated by the failure of  the CFA/IFA injection protocol to gener-
ate NO-producing cells and to confer suppressor potential to CD11b+ myeloid spleen cells. Although the 
splenic infiltrates into the T cell areas after LPS/IFN-γ injection in CFA/CFA mice and bulk cultures of  
BM-MDSCs contained monocytic and granulocytic cells, we identified the M-MDSCs as primary NO pro-
ducers and suppressor cells and did not further address the granulocytic subset. The granulocytic MDSC 
infiltration into the T cell areas may have a partial role for NO in DC killing, but a clear understanding of  
their function within the T cell areas requires further investigation.
The data obtained here follow the same 2-step rules for licensing and activation of  MDSCs as described 
before (21, 22). As a critical first step, the conversion of  classical Ly6Chi monocytes into L-Mono was identi-
fied as a prerequisite for the acquisition of  M-MDSC suppressor function. In our system, GM-CSF–mediated 
monocyte licensing was identified as a critical component for subsequent M-MDSC generation (21). GM-CSF 
is a generally accepted inducer of  MDSCs (2). Others have shown that M. tuberculosis components increased 
the serum GM-CSF levels when injected into mice (33) and that TB patients show elevated GM-CSF levels 
in pleural effusions similar to those of  tumor patients (34). In this study, the expansion of  the myeloid cells 
was observed in spleens of  CFA-injected mice. However, we did not assess whether M. tuberculosis release 
from CFA and its transport to the BM can directly promote myelopoiesis or whether M. tuberculosis induces 
indirectly myeloid cell expansion or monocyte licensing by inducing a myeloid growth factor. An indirect 
stimulatory effect of  pathogen components, such as β-glucan on GM-CSF and IL-1β–induced proliferation of  
early hematopoietic cells, has been reported to induce trained immunity (35). BCG infection can induce met-
abolic changes in monocytes associated with trained immunity (36). However, changes observed as monocyte 
training were found not to act directly on differentiated monocytes but to occur by epigenetic modifications 
on early myeloid precursors, which then result in trained monocytes (35, 37). This BCG-mediated training 
effect resulted in a better secondary innate immunity against viral infection, which correlated with IL-1β 
upregulation, while GM-CSF was not investigated (38). If  pathogens induce epigenetic modifications at the 
chromatin level, then the use of  histone deacetylase (HDAC) inhibitors may allow a switch from monocyte 
training toward MDSC development. In fact, in vitro the GM-CSF–mediated BM precursor development 
into monocytic BM-DCs was blocked by the HDAC inhibitor trichostatin A and resulted in NO-produc-
ing M-MDSCs (39). Whether M. tuberculosis vaccination can also induce chromatin modifications and how 
such epigenetic modifications and their inhibition may balance the GM-CSF–dependent trained monocyte or 
M-MDSC generation requires further in vivo investigations.
It is unclear whether epigenetic modifications induced by M. tuberculosis are restricted to myeloid pre-
cursors or whether they can also occur in differentiated monocytes. Again, in vitro evidence suggests that 
the late developmental switch from differentiated human CD14+ monocytes into either macrophages or 
DCs is directed by epigenetic changes (40). We found previously that in GM-CSF differentiated BM-MD-
SC cultures, transcriptional and translational changes occur that are prerequisite for their development into 
M-MDSCs (21). Thus, it is tempting to speculate that, in M. tuberculosis–induced M-MDSC generation, 
epigenetic changes also can occur at a differentiated monocyte stage.
Previously we demonstrated that proinflammatory cytokines (21) or systemic LPS/IFN-γ adminis-
tration in mice (22) can serve as factors for the second activation step that converts L-Mono into M-MD-
SCs. Here, we found that also M. tuberculosis/IFN-γ injections could induce DC killing, although to a 
lesser extent. We believe that this reduced efficiency is due to the whole bacteria M. tuberculosis prepara-
tion and that standardized smaller particles or defined soluble components as available in M. tuberculosis 
vaccines for clinical studies may reveal more clear results.
The IFN-γ component of  our challenging protocol appears as a major component of  MDSC activa-
tion, and blocking by antibodies or genetic deficiency of  the receptor largely abrogates MDSC activation of  
NO production (21, 22). In TB infection, the M. tuberculosis challenge may directly occur in the lung or after 
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bacterial dissemination to the spleen and other sites. In such a scenario, infiltrating NK cells or effector T 
cells may typically account for local IFN-γ production.
Injection of  LPS/IFN-γ induced MDSC accumulation in T cell areas. Since this process occurred very 
rapidly, we presume that MDSC infiltration starts from the red pulp and bridging channels and not by 
recruitment from the BM. Such an intrasplenic translocation has been observed before for DCs that moved 
from the bridging channels to the white pulp after LPS injection into mice (41), and DC homing into the 
splenic T cell areas was proposed to depend on CCR7 (42), similar to lymph nodes. However, lymph node 
homing of  MDSCs is poor in most animal models investigated (43, 44), and FACS analysis of  spleen 
MDSCs after CFA/CFA plus LPS/IFN-γ treatment did not reveal CCR7 expression (data not shown), 
indicating that other homing receptors may mediate this effect.
Induction of  T cell apoptosis by MDSCs via NO production belongs to the earliest suppressor mecha-
nisms that have been described for MDSCs in vivo (4, 45) and is now considered as a prominent mechanism 
for MDSC-mediated suppression (1, 46). However, MDSC-derived NO has been demonstrated to affect T 
cells mainly in vitro or ex vivo, such as by restimulation of  spleen cells from Trypanosoma-infected mice (47). 
In our study, suppression of  CD3/CD28 antibody-induced T cell proliferation and apoptosis in vitro and 
ex vivo was entirely dependent on the NO-dependent mechanism, as shown by the use of  the L-NMMA 
inhibitor or Nos2-deficient MDSCs. From these in vitro and ex vivo findings it had been extrapolated that the 
abrogation of  suppressor function in mice by injection of  L-NMMA or the use of  Nos2–/– mice must rely on 
the direct suppression of  M-MDSCs on T cells, although this had not been formally proven. Our data indi-
cate that although NO-dependent T cell apoptosis can be readily observed in vitro, apoptotic CD4+ or CD8+ 
T cells were not found in our setting in vivo, both after CFA/CFA immunizations alone or with additional 
LPS/IFN-γ challenge. Since the clearance of  apoptotic cells is highly efficient and T cells are continuously 
circulating, it may well be possible that we missed the detection of  T cell apoptosis. We also cannot exclude 
the presence of  a low frequency of  activated M. tuberculosis–specific T cells as specific targets of  M-MDSC 
suppression within the general pool of  all and mostly resting T cells. On the other hand, our ex vivo T cell 
stimulation data showing an impaired proliferation in presence of  CD11b+ cells could be fully and immedi-
ately reconstituted when CD11b+ cells were removed. This indicates that T cells of  CFA/CFA-immunized 
mice are under reversible suppression of  M-MDSCs but may not be deleted by apoptosis.
Instead, we discovered that cDCs and pDCs can be direct targets of  iNOS-dependent killing by M-MD-
SCs in vivo; thus, they represent what we believe to be a novel mechanism of  indirect M-MDSC–mediated 
T cell suppression in addition to the known direct effects on T cells. While CFA/CFA immunization was 
required for CD11b+ spleen cells to acquire a high NO-producing and T cell suppressive capacity ex vivo, 
these mice did not show persistence of  iNOS+ cells or elevated NO production in the T cell areas 3 days 
after the last CFA injection. However, DC apoptosis was detected after a short-term systemic LPS/IFN-γ 
and to a lesser extent after M. tuberculosis/IFN-γ challenge. M-MDSCs were recruited into the white pulp 
T cell area, in which they seek close contacts with DCs after 6 hours and finally induced cDC and pDC 
apoptosis after 24 hours. Importantly, cDCs did not and pDCs did only partially die from apoptosis by 
the LPS/IFN-γ treatment alone. DC apoptosis was abrogated in Nos2–/– mice, as observed via annexin V 
binding by FACS and detected by TUNEL staining in splenic cryosections. Our in vitro data also indicated 
that BM-DCs could be killed by M-MDSCs through apoptosis induction by NO. Together, our data demon-
strate for the first time to our knowledge iNOS-mediated suppressor effects of  MDSCs in vivo. In addition 
to the iNOS-dependent killing on T cells that could be observed in vitro and ex vivo, these in vivo results 
now demonstrate mycobacteria-induced iNOS-dependent killing of  DCs.
Our results regarding the abrogation of  adjuvant effects in CFA/CFA mice may relate to human TB 
vaccination studies. BCG revaccinations are not recommended anymore due to a lack of  additional pro-
tective effects (48). The induction of  MDSCs was not investigated in these individuals. In contrast, boosted 
T cell responses could be observed when an Ag85A M. tuberculosis subunit vaccine was applied within a 
human adenovirus 5 vector after a BCG prevaccination (49). These findings may indicate that either whole 
mycobacteria are required to induce MDSCs or that specific subcomponents may lack this ability. Alterna-
tively, the subsequent use of  antigens from 2 different mycobacterial species as vaccines may somehow blur 
a pathogen-specific MDSC induction. In a recent study, adolescents revaccinated with BCG or H4:IC31 
(containing the TB10.4 and Ag85A M. tuberculosis antigens) after they received BCG vaccination during 
infancy, showed boosted CD4+ T cell responses within PBMCs when restimulated with vaccine antigens 
in vitro in the BCG revaccination group (50). These results may indicate that a longer time period between 
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first (infancy) and second (adolescence) vaccination may be beneficial for boosting T cell responses out of  
bulk PBMCs as compared with our prime/boost regimen with an interval of  only 12 days.
 In conclusion, our data suggest that a single vaccination with dead M. tuberculosis, such as performed here 
with CFA, induces a similar MDSC accumulation in the spleen as observed before in the draining lymph nodes 
and blood after live s.c. BCG injection into mouse ears (23). We found that a single CFA injection or a CFA/
IFA sequence of injections still shows intact T cell proliferation in the spleen in accordance to the well-described 
adjuvant effects of CFA, while others observed local suppressive effects in skin and lymph nodes using single 
live BCG injections (23). While after live BCG immunization, a clear Ly6Chi population was not distinguishable 
from the general Ly6C+ monocytic cell pool, the functional consequences of BCG or M. tuberculosis vaccinations 
are very similar in their NO-dependent suppressive effect on T cells, dampening the in vivo priming (23), consis-
tent with induction of the M-MDSC subset. In our case, only repeated CFA vaccination fully activated MDSC 
suppressor activity at a systemic level. This delay or weaker MDSC development is potentially due to the use 
of dead material instead of live bacteria. While MDSC infection by BCG (23) and M. tuberculosis (11) has been 
observed, we can exclude live bacterial dissemination to the spleen and rather indirect effects may have mobi-
lized splenic MDSC accumulation in our experimental setting. As a potentially novel suppressor mechanism, we 
identified NO-dependent DC killing in the splenic white pulp T cell areas. Since impaired memory T cell gener-
ation and lack of protection have been found also in experimental M. tuberculosis infections of mice (11) and in 
human TB patients (9, 10), our findings in mice may have implications for TB vaccinations in humans and sug-
gest that investigations on potential MDSC induction and DC killing also in human trials should be considered.
Methods
Mice. C57BL/6J (Charles River) and Nos2–/– (B6.129P2-Nos2tm1Lau/J, The Jackson Laboratory) mice were bred 
in our animal facilities, kept under specific pathogen–free conditions, and used at an age of  7–12 weeks.
In vivo treatment of  mice. C57BL/6 mice were injected s.c. into the flanks with 100 μL CFA/PBS emul-
sions at a 1:1 ratio. The CFA was further enriched with M. tuberculosis as described for myeloid cell expan-
sion (51). Revaccination was performed s.c. either with 50 μL IFA/PBS emulsion or 50 μL CFA/PBS 
emulsion. For some experiments, mice were injected with 10 μg LPS plus 1 μg IFN-γ i.p. for 6 hours or 
24 hours or 10 μg sonicated heat-killed M. tuberculosis (Difco) plus 1μg IFN-γ to provoke iNOS induction.
Cell preparation. BM-MDSCs and BM-DCs were generated as described previously (20, 52). Briefly, BM 
cells from C57BL/6 mice were seeded at 3 × 106 per 100 mm petri dish (Greiner) in 10 mL of fresh RPMI1640 
medium (PAA) containing 10% heat-inactivated FCS from GIBCO (termed R10), supplemented with 100 U/
mL penicillin (MilliporeSigma), 100 μg/mL streptomycin (MilliporeSigma), 2 mM L-glutamine (MilliporeSig-
ma), 50 μM β-mercaptoethanol (MilliporeSigma), and 10% GM-CSF supernatant (53). BM-MDSCs were used 
at day 3 for assays. Murine BM-DCs were generated in the same way, but on day 3 of culture, 10 mL complete 
RPMI medium supplemented with 10% GM-CSF–containing supernatant was added. On day 6, 10 mL of the 
medium was removed, and fresh medium was added as at day 3. BM-DCs were used at day 7–8 of culture.
Reagents. GM-CSF was obtained from supernatant of  cell lines transfected with the murine GM-CSF 
gene (53). IFN-γ (0.5 μg/mL) was purchased from Immunotools. CFA/IFA, LPS (1 μg/mL), NG-Meth-
yl-L-arginine acetate salt (L-NMMA, 500 μM) and 1,2-Diaminoanthraquinone (DAQ, 10 μM) were pur-
chased from MilliporeSigma. Killed and dried M. tuberculosis (H37Ra strain) was purchased from Difco. All 
concentrations were used as indicated in the figures or legends.
Flow cytometry. The murine directly conjugated antibodies CD11b-PerCP-Cy5.5 (M1/70), CD11b-APC 
(M1/70), B220-Pacific Blue (RA3-6B2), Gr-1-Alexa Fluor 647 (RB6-8C5), Ly6G-PerCP-Cy5.5 (1A8), 
Ly6G-APC/Fire (1A8), Ly6C-Alexa Fluor 647 (HK1.4), Ly6C-Brilliant Violet 510 (HK1.4), CD4-APC 
(GK1.5), CD4-PerCP-Cy5.5 (GK1.5), CD8-PerCP-Cy5.5 (53-6.7), CD8-APC (53-6.7), CD11c-PE-Cy7 
(N418), CD25-FITC (PC61), CD69-Alexa Fluor 488 (H1.2F3), CD69-APC (H1.2F3), Streptavidin Bril-
liant Violet 421, and annexin V-FITC were all purchased from Biolegend. Propidium iodide was purchased 
from R&D System. iNOS-PE (CXNFT) was obtained from eBioscience.
Cells were stained in PBS containing 0.1% BSA, 0.1% sodium azide, and 5% fetal bovine serum in the 
dark for 30 minutes on ice. For intracellular iNOS detection, cells were first labeled for surface markers and 
then washed and subsequently fixed with 2% PFA for 10 minutes at room temperature. Cells were next 
permeabilized and stained with FACS buffer containing saponin (0.5%) for 1 hour at 4°C together with the 
marker-specific antibody. Samples were washed once in staining buffer and measured with a FACS Calibur 
or LSR II (Becton Dickinson). Results were analyzed with FlowJo software (Tree Star).
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Cytospins, tissue staining, and microscopy analysis. For visualization of  the in vitro DC killing assay, 
24- or 48-hour cocultured cells were collected and washed and 5 × 105 cells were deposited onto a poly-
L-lysine–coated glass slide (Poly-Prep, MilliporeSigma) and allowed to precipitate for 1 hour at 37°C. 
Cells were next fixed in 2% PFA for 10 minutes at room temperature, washed twice in PBS, and blocked 
and permeabilized in PBS containing 2% goat serum with 0.1% Triton X-100 and 0.1% BSA for 20 
minutes at room temperature. The primary antibody CD11c-Alexa Fluor 594–conjugated (clone N418, 
Biolegend) was diluted 1:100 in PBS and incubated overnight at 4°C. Slides were washed several times 
in PBS and TUNEL assay was subsequently performed (see below) for the detection of  apoptotic cells. 
Nuclei were stained using DAPI (AppliChem). Spleens from euthanized mice were collected and trans-
ferred into tubes containing OCT compound (Tissue-Tek, SAKURA), immediately frozen, and stored 
at (–80°C). Organs were subsequently cut into 10-μm-thick slices using a Cryotome (Leica), and tissue 
was stained using the same procedure and buffers described for the cytospin cells. Finally, slides were 
repeatedly washed in PBS, dried, and mounted with Fluoromount-G (SouthernBiotech). Tissue sections 
were all visualized and further analyzed with an Imager.Z1m immunofluorescence microscope (Zeiss). 
Primary antibodies used for tissue cell detection were as follows: Gr-1-Biotin (RB6-8C5) and CD11b-Bi-
otin (M1/70) was purchased from BD; CD11b-Alexa Fluor 488 (M1/70) was obtained from Serotec; 
F4/80-Alexa Fluor 488 was purchased from Bio-Rad; and CD45R/B220-Alexa Fluor 647 (RA3-6B2), 
Ly6G-purified (1A8), CD115-Biotin (AFS98), and CD11c-Biotin (N418) were purchased from Bioleg-
end. A polyclonal iNOS antibody was used at 1:20,000 dilution (54). Secondary antibodies Goat anti-
Rat IgG DyLight 549 and Streptavidin DyLight 549 were obtained from Rockland; Goat anti-Rat IgG 
Alexa Fluor 488 and Streptavidin Alexa Fluor 488 were purchased from Life Technologies; Streptavidin 
Cy3 was obtained from Biolegend; Goat anti-Rabbit IgG DyLight 488 and Goat anti-Rabbit IgG Cy3 
were both purchased from Jackson ImmunoResearch. For direct NO detection, DAQ was used (Milli-
poreSigma, D11582). The frozen tissue was allowed to thaw at room temperature, washed once with 
1× PBS, and incubated at 37°C with DAQ in PBS at the concentration of  10 μM for 45 minutes. After 
washing the slides with PBS, the tissue was costained for other markers (B/T cells), as described before 
but without fixation and permeabilization steps and at room temperature. Apoptosis was detected by 
the FVF reagent, a green fluorescent cell-permeable polycaspase inhibitor to target caspase-1, -2, -3, -6, 
-8, -9, or -10 (AAT Bioquest, ABD-13470; distributor Biomol) or by TUNEL assay (In Situ Cell Death 
Detection Kit, Roche), both of  which were used according to the manufacturers’ instructions. Briefly, 
the samples were stained with Enzyme solution diluted 1:10 with labeling solution (Roche) for 1 hour at 
37°C. After 3 washing steps, the slides were embedded in Fluoromount G (SouthernBiotech) and cov-
ered with a coverslip. Images were scanned using an LSM 510 Meta Confocal Microscope (Zeiss) and 
the ZEN Black 8.1 software (Zeiss) and processed via the ImageJ 1.51h software (NIH).
NO measurement. Induction of  NO release was performed as described previously by cell stimulation 
overnight with either IFN-γ (0.5 μg/mL, Peprotech) plus LPS (1 μg/mL, MilliporeSigma) (22) or 50 μg/
mL heat-killed M. tuberculosis (Difco). NO was measured as nitrite accumulation using the Griess reaction 
(55). Briefly, 50 μL cell culture supernatant was put into a 96-well ELISA-plate (Corning) as duplicates 
with titrated NaNO2 (MilliporeSigma) in R10 medium serving as a standard. An aqueous solution of  0.1% 
naphtylethylendiamine dihydrochloride (MilliporeSigma) and 1% sulfanilamide (MilliporeSigma) in 5% 
H3PO4 (Merck) in water was mixed 1:1, and 50 μL of  this solution was added to 50 μL of  the samples. The 
evoked color reaction was measured after 10 minutes in the ELISA reader (Molecular Devices) at 492 nm, 
and nitrite concentrations were calculated from the sodium nitrite standard curve.
Ex vivo suppressor assay. Organs were processed following standard protocols until single-cell suspensions 
were obtained. CD11b+ cells were positively sorted by MACS beads and separated through LS columns 
(Miltenyi Biotec). Sorted cells were tested in a T cell proliferation inhibition assay for their suppressive 
capacity. Bulk lymph nodes cells from C57BL/6 mice were labeled with CFSE (MilliporeSigma), plated 
at a fix concentration of  2 × 106 cells in a 24-well plate in 2 mL R10 media, and stimulated with soluble 
CD3/CD28 antibodies at a final concentration of  2.5 μg/mL. Sorted CD11b+ cells were titrated and added 
to the T cells at a different ratio. Cells were cocultured over 4 days and their proliferation was measured as 
CFSE dilution by FACS analysis separately in CD4- and CD8-stained T cell subsets. For the ex vivo bulk 
T cell proliferation assay, spleens from untreated or treated mice were depleted or not from CD11b+ cells 
using MACS beads. Splenocytes were then labeled with CFSE and stimulated with soluble CD3/CD28, 
and their proliferation was measured after 4 days in culture as described above.
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In vitro apoptosis assays. Bulk lymph nodes cells from C57BL/6 mice were labeled with eFluor670 (eBio-
science), plated at a fix concentration of  2 × 106 cells in a 24-well plate in 2 mL R10 media, and stimulated 
with soluble CD3/CD28 antibodies at a final concentration of  2.5 μg/mL. L-Mono, as obtained after 
culture of  BM cells for 3 days in GM-CSF, from WT or Nos2–/– mice were prepared as described before, 
titrated, and added to the T cells at a different ratio. Cells were allowed to interact for 24, 48, and 72 hours, 
and their apoptosis and necrosis induction (annexin V detection and addition of  propidium iodide) as 
well as the variability of  different surface markers expression were measured by FACS analysis. LPS- or 
CpG-matured DCs were eFluor670-labeled and plated at a fixed concentration of  3 × 105 cells/well in a 
round-bottomed, 96-well plate. BM-MDSCs from WT or Nos2–/– mice were used as bulk cells or sorted by 
FACS into CD11b+Ly6G–Ly6Chi monocytic (M-MDSCs) and CD11b+Ly6G+Ly6Clo granulocytic subsets 
(G-MDSCs). MDSCs remained resting or activated by 20 μg/mL heat-killed M. tuberculosis before they 
were added at the indicated ratios to the respective cells. Annexin V expression in eFluor670+ cells was 
measured by FACS after 24 and 48 hours coculture.
Software-based quantification of  TUNEL+/CD11c+ cells. Images were processed with the StrataQuest soft-
ware (TissueGnostics) as described previously (32). Using that software, 3 markers were applied: CD11c, 
TUNEL, and B220. The B cell area was visualized by B220 for subsequent selection of  the T cell area. 
To achieve optimal cell detection the following parameters were adjusted: (a) CD11c cellular mask and 
(b) TUNEL shades within the CD11c cellular mask. Scattergrams were created for the evaluation of  
TUNEL+/CD11c+ cells, allowing the visualization of  corresponding positive cells in the source region of  
interest using the real-time back gating feature. A global measurement algorithm was performed allowing 
the quantification of  CD11c+/TUNEL+ cells within the T cell area of  spleen sections. For each section 
more than 10,000 nucleated cells were assessed, of  which more than 100 CD11c+ DCs per T cell area were 
further analyzed for detection of  TUNEL staining.
Statistics. Figures were created and statistics were calculated using the Prism 6 (GraphPad Software) 
program. Details on the statistical tests used are provided in the figure legends and include 1-way ANOVA 
with multiple comparisons, 2-way ANOVA, Tukey’s post test, and 2-tailed t test. P values of  less than 0.05 
were considered significant.
Study approval. All animal experiments were performed according to the national and local animal 
protection laws as well as after approval and under control of  the local authorities (Regierung von Unter-
franken, Würzburg, Germany) (no. 55.2-2531.01-64/11 and -2-200).
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